Skip to content

Transcutaneous Injection and Transconjunctival Injection of Triamcinolone Acetonide for Upper Eyelid Retraction in Thyroid Eye Disease

Transcutaneous Injection and Transconjunctival Injection of Triamcinolone Acetonide for Upper Eyelid Retraction in Thyroid Eye Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108834
Enrollment
Unknown
Registered
2025-09-08
Start date
2025-09-08
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid eye disease

Interventions

Observation group of subconjunctival injection under the dome of the eye:None
Observation group of percutaneous injection beside the levator palpebrae muscle.:None

Sponsors

Wenzhou Medical University Affiliated Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older; 2. The upper eyelid margin is at or above the corneal limbus when looking straight ahead (MLD1=0mm), or the difference in the distance from the upper eyelid margin to the corneal reflection (MRD1) of the affected eye and the contralateral eye is >=1mm; 3. Abnormal thyroid function indicators (T3, T4, FT3, FT4, TSH) or elevated TRAB. In the case of bilateral involvement, select the eye with the more severe condition to enter the group.

Exclusion criteria

Exclusion criteria: 1. Exophthalmos greater than 20mm, accompanied by strabismus or restrictive eye movement disorders, combined with optic nerve compression; 2. Use of glucocorticoids, immunosuppressants, or biological agents systemically or locally within 3 months before treatment; 3. Local botulinum toxin injection within the past six months; 4. After orbital decompression surgery; 5. After orbital radiotherapy; 6. Contralateral eye accompanied by severe myasthenia gravis type.

Design outcomes

Primary

MeasureTime frame
Distance from the upper eyelid margin to the corneal light reflex (MRD1);

Secondary

MeasureTime frame
IOP;Before each injection;

Countries

China

Contacts

Public ContactWang Mengdi

Wenzhou Medical University Affiliated Eye Hospital

714867489@qq.com+86 18067985713

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026